A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients with Leptomeningeal Disease (LMD)
MD Anderson Study Status
This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Melanoma, Metastatic Uveal Melanoma, Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Isabella Glitza Oliva
Melanoma Medical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.